Teleflex Incorporated ($TFX) Stock Forecast: Up 10.4% Today

What is Teleflex Incorporated?

Teleflex Incorporated (TFX) is a medical technology company specializing in critical care and high acuity hospital markets. Today, TFX experienced a strong bullish movement in the stock market.

Why is Teleflex Incorporated going up?

TFX stock is up 10.4% on Dec 9, 2025 15:42

• The bullish movement in TFX stock today can be attributed to the completion of the $2.03 billion sale of its Acute Care, Interventional Urology, and OEM businesses. This strategic divestiture is part of Teleflex's plan to optimize its portfolio and focus on core markets, which has likely been well-received by investors.
• The sale will provide Teleflex with approximately $1.8 billion in net proceeds, which the company plans to utilize for returning capital to shareholders through share repurchases and paying down debt. This capital allocation strategy could be seen as a positive signal by investors, driving up the stock price.
• The acquisition of Teleflex Medical OEM by private equity firms Montagu and Kohlberg for $1.5 billion is also a significant development. This move is expected to position Teleflex Medical OEM as an independent global contract developer and manufacturer, potentially unlocking new growth opportunities and enhancing innovation capabilities.
• Overall, the market seems to be reacting positively to Teleflex's strategic initiatives and the potential for accelerated growth and value creation following the divestiture and acquisition deals.

TFX Price Chart

TFX Technical Analysis

TFX News

Montagu, Kohlberg to Acquire Teleflex Medical OEM for $1.5B

Middle-market private equity firms Montagu and Kohlberg have agreed to acquire Teleflex Medical OEM from Teleflex Inc. for $1.5 billion. After the transaction, expected to close in the second half of 2026, Teleflex Medical OEM will operate as an independent global contract developer and manufacturer, led by current president Greg Stotts. The acquisition aims to accelerate growth by expanding its customer base and investing in innovation with the support of Montagu and Kohlberg's expertise.

https://www.mpo-mag.com/breaking-news/montagu-kohlberg-to-acquire-teleflex-medical-oem-for-1-5b/

Teleflex completes $2.03B sale of Acute Care, Urology, OEM businesses

Teleflex has announced the completion of its $2.03 billion sale of its Acute Care, Interventional Urology, and OEM businesses to two separate buyers: Intersurgical Ltd and Montagu and Kohlberg. The divestiture is part of Teleflex's strategy to optimize its portfolio, focusing on core critical care and high acuity hospital markets. The company plans to use the net proceeds of approximately $1.8 billion to return capital to shareholders through share repurchases and to pay down debt.

https://www.massdevice.com/teleflex-completes-2b-sale-acute-care-urology-oem/

Montagu and Kohlberg to acquire Teleflex Medical OEM for $1.5 billion

Private equity firms Montagu and Kohlberg are set to acquire Teleflex Medical OEM from Teleflex Incorporated for $1.5 billion. The transaction is structured as a carve-out, with Teleflex Medical OEM operating independently after closing, which is expected in the second half of 2026. This acquisition is part of Teleflex's strategic initiatives, which include selling other businesses and a share repurchase program.

https://uk.investing.com/news/company-news/montagu-and-kohlberg-to-acquire-teleflex-medical-oem-for-15-billion-93CH-4408972

Montagu and Kohlberg to Acquire Teleflex Medical OEM in a Carve-out Transaction

Montagu and Kohlberg, two private equity firms, have announced a definitive agreement to acquire Teleflex Medical OEM from Teleflex Incorporated for $1.5 billion in a carve-out transaction. Upon completion, Teleflex Medical OEM will operate as an independent company focusing on custom-engineered interventional catheter components and surgical fibers. This acquisition aims to accelerate investment in innovation and expand its customer base, leveraging the firms' expertise in healthcare investments and carve-out transactions.

https://www.businesswire.com/news/home/20251208550931/en/Montagu-and-Kohlberg-to-Acquire-Teleflex-Medical-OEM-in-a-Carve-out-Transaction

Teleflex Incorporated Announces $2.03 Billion Sale of Acute Care, Interventional Urology, and OEM Businesses

Teleflex Incorporated has announced the sale of its Acute Care, Interventional Urology, and OEM businesses for a total of $2.03 billion in cash. This strategic move aims to focus the company on its core critical care and high acuity hospital markets, with proceeds primarily funding share repurchases and debt reduction, including a newly authorized $1 billion share repurchase program. The transactions are expected to close in the second half of 2026.

https://www.quiverquant.com/news/Teleflex+Incorporated+Announces+%242.03+Billion+Sale+of+Acute+Care%2C+Interventional+Urology%2C+and+OEM+Businesses

Trending Today

Filecoin ($FIL) Crypto Forecast: Up 5.0% Today

PancakeSwap ($CAKE) Crypto Forecast: Down 5.1% Today

Silver ($XAG) Commodity Forecast: Up 5.0% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Up 5.7% Today

Comcast Corporation Class A Common Stock ($CMCSA) Stock Forecast: Up 5.0% Today

National Oilwell Varco Inc. ($NOV) Stock Forecast: Down 5.1% Today

Phillips 66 ($PSX) Stock Forecast: Down 5.1% Today

Pfizer Inc. ($PFE) Stock Forecast: Down 5.1% Today

Humana Inc. ($HUM) Stock Forecast: Down 5.1% Today

Cytokinetics, Incorporated ($CYTK) Stock Forecast: Down 5.0% Today

Teleflex Incorporated Price History

15.08.2025 - TFX Stock was down 5.1%

• The enrollment of the first patient in the DUBSTENT DIABETES trial, focusing on improving PCI outcomes for diabetic patients, could be seen as a positive development for TFX.
• However, the market might have reacted negatively to the uncertainty surrounding the trial's success and potential regulatory hurdles.
• Investors may be concerned about the competitive landscape in the diabetes treatment market, leading to a sell-off of TFX shares.
• Overall, the bearish movement in TFX's stock could be attributed to the mixed sentiments surrounding the trial's outcomes and the competitive pressures in the industry.

09.11.2025 - TFX Stock was up 8.8%

• The bullish movement in TFX may be linked to a theory emphasizing the company's strategic turnaround and potential upside.
• An analysis suggests TFX could be undervalued by up to 74.2%, sparking investor interest and increased buying activity.
• The recent acquisition of BIOTRONIK's Vascular Intervention business and positive FY 2025 EPS guidance by the company likely contributed to the bullish momentum.
• Despite concerns from analysts lowering price targets and ratings, the overall positive outlook on TFX's growth prospects and strategic initiatives appears to have driven the stock higher.

09.11.2025 - TFX Stock was up 10.4%

• The bullish movement in TFX stock today can be attributed to the completion of the $2.03 billion sale of its Acute Care, Interventional Urology, and OEM businesses. This strategic divestiture is part of Teleflex's plan to optimize its portfolio and focus on core markets, which has likely been well-received by investors.
• The sale will provide Teleflex with approximately $1.8 billion in net proceeds, which the company plans to utilize for returning capital to shareholders through share repurchases and paying down debt. This capital allocation strategy could be seen as a positive signal by investors, driving up the stock price.
• The acquisition of Teleflex Medical OEM by private equity firms Montagu and Kohlberg for $1.5 billion is also a significant development. This move is expected to position Teleflex Medical OEM as an independent global contract developer and manufacturer, potentially unlocking new growth opportunities and enhancing innovation capabilities.
• Overall, the market seems to be reacting positively to Teleflex's strategic initiatives and the potential for accelerated growth and value creation following the divestiture and acquisition deals.

08.04.2025 - TFX Stock was up 5.4%

• A Board Member at Teleflex, Duncan, displayed confidence in the company's future prospects by acquiring stock options.
• Teleflex's Q1 earnings exceeded expectations due to its diverse product portfolio and strong performance in key segments, fostering investor optimism.
• Despite an investigation by the Rosen Law Firm concerning potential securities claims, Teleflex's stock performance remained largely unaffected, with positive earnings results taking precedence.

28.01.2025 - TFX Stock was down 5.8%

• Surpassing Q4 earnings estimates and benefiting from a diversified product portfolio, TFX faced a bearish movement possibly due to a decline in gross margin.
• The announcement of the planned retirement of the Chief Financial Officer may have prompted concerns among investors regarding future financial strategies and leadership stability.
• While the quarterly dividend declaration was favorable, it may not have been enough to counter the impact of the CFO's retirement and the gross margin decline on investor sentiment.
• Overall, market participants seem to be taking a cautious approach towards TFX's future financial performance and strategic direction, influencing the stock price to move bearishly.

01.04.2025 - TFX Stock was down 6.3%

• Despite beating Q1 earnings and revenue estimates, the stock experienced a bearish movement, indicating that the market may have had higher expectations.
• The FDA clearance for expanded indications of one of Teleflex's medical devices may not have had the positive impact on the stock price as anticipated.
• The ongoing investigation by Pomerantz Law Firm into claims on behalf of investors could have raised concerns among shareholders, leading to the bearish market movement.
• Overall, the combination of high expectations, mixed reactions to regulatory news, and investor scrutiny may have contributed to the bearish trend in TFX stock today.

01.04.2025 - TFX Stock was down 5.1%

• The bearish movement in TFX stock could be due to investor concerns raised by the ongoing investigation by Pomerantz Law Firm regarding claims on behalf of investors.
• Despite the positive news of FDA clearance for expanded indications of their medical device, the uncertainty surrounding the investigation might have overshadowed the potential market impact.
• Investors may be cautious until more clarity is provided on the outcome of the investigation, leading to the downward movement in TFX stock price today.

25.08.2025 - TFX Stock was down 5.0%

• The market sentiment towards TFX has been bearish today.
• The decrease in TFX stock today might be linked to a recent comparison between TFX and PEN, discussing the preferable investment option. The resulting uncertainty potentially prompted some investors to sell their TFX shares, contributing to the bearish trend.

11.10.2025 - TFX Stock was up 5.1%

• The upward trend in TFX stock may be linked to its third-quarter earnings report surpassing analyst forecasts.
• Teleflex's announcement of a quarterly dividend could also be a contributing factor to the positive outlook among investors, particularly appealing to those seeking dividends.
• The combination of outperforming earnings projections and the introduction of a dividend likely strengthened investor confidence in Teleflex's financial stability and future potential, driving the increase in the stock price.

08.06.2025 - TFX Stock was up 1.9%

• The acquisition of BIOTRONIK's vascular intervention business by Teleflex (TFX) resulted in a 2.9% increase in TFX stock price.
• This acquisition is viewed as a strategic move to improve TFX's presence in cath lab and its innovation pipeline.
• Investor confidence in TFX's growth prospects was positively influenced by this acquisition.

06.10.2025 - TFX Stock was down 13.1%

• The announcement of a quarterly dividend may have led to a bearish movement in the stock.
• Investors might be concerned that the dividend payout could impact the company's cash reserves or future growth prospects.
• The market may be reacting negatively to the dividend news, possibly indicating a shift in investor sentiment towards the stock.
• Overall, the bearish movement in TFX could be attributed to profit-taking by investors following the dividend announcement.

31.06.2025 - TFX Stock was up 6.6%

• TFX stock saw a significant increase in value today.
• The company's Q2 earnings and revenues exceeded expectations, reflecting robust financial results.
• The recent declaration of a quarterly dividend by Teleflex's Board of Directors may have enhanced investor trust and drawn more interest from potential buyers to the stock.
• Both the impressive earnings performance and the dividend declaration likely contributed to the positive movement in TFX's stock price.